珍香胶囊对裸鼠原位移植的人胃癌的抗癌作用 ; ANTITUMOR EFFECT OF ZHENXIANG CAPSULE ON THE HUMAN STOMACH CANCER XENOTRANSPLANTED ORTHOTOPICALLY IN NUDE MICE

目的 :了解珍香胶囊对裸鼠原位移植的人胃癌的疗效 ,为临床试验提供科学依据。方法 :用珍香胶囊分别对人胃低分化腺癌SGC 790 1以及人胃高分化腺癌MKN 2 8裸鼠原位移植模型进行治疗。实验分 5组 :珍香胶囊高浓度组 (480 0mg/kg·bw)、中浓度组 (2 40 0mg/kg·bw)、低浓度组 (12 0 0mg/kg·bw)以及阳性对照组 (丝裂霉素C 1mg/kg·bw)和阴性对照组 (生理盐水 )。珍香胶囊灌胃给药 ,每天 2次 ,连续给药 40次 ,丝裂霉素C皮下注射给药 ,每 2天 1次 ,共给药 10次。实验以荷人胃癌裸鼠的生命延长率、胃指数、血清唾液酸 (SA)含量作为疗效评价指标。实验重复 3次。结果 :①珍香胶囊高、中、低三剂量对荷人胃癌SGC 790 1裸鼠生命延长率分别为 5 7.78%～ 72 .0 3% (P <0 .0 1) ,42 .2 2 %～ 5 6 .5 9% (P <0 .0 1)、2 8.13%～ 33.79%(P <0 .0 1) ,阳性对照丝裂霉素C对荷人胃癌SGC 790 1裸鼠生命延长率为 5 2 .5 8%～ 6 0 .0 2 % (P <0 .0 1) ;②经珍香胶囊高、中剂量治疗后 ,荷人胃癌MKN 2 8裸鼠的胃指数、血清SA含量显著减少 (P <0 .0 1或P <0 .0 5 )。结论 :在裸鼠可耐受的剂量下 ,珍香胶囊对裸鼠原位移植的人胃低分化腺癌SGC 790 1以及人胃高分化腺癌MKN 2 8均有明显的抗癌作用 ,且随着剂量增加 ,其抗癌疗效增? ; Purpose: The antitumor effect of Zhenxiang capsule(ZXC) was studied on the human stomach cancer xenotransplanted orthotopically in nude mice in order to provide scientific evidence supporting for clinical use. Methods: A treatment was carried out with ZXC on the nude mice orthotopically transplanted model of human stomach poor differentiated adenocarcinoma SGC 7901 and the human well differentiated adenocarcinoma MKN 28. The animals were divided into 5 groups: the high dose group of ZXC with a dose of \{4 800\} mg/kg·bw, the medium dose group of ZXC with a dose of 2 400 mg/kg·bw, and the low dose group with a dose of 1 200 mg/kg·bw, the positive control group of mitomycin C with a dose of 1 mg/kg·bw, and the negative control group with normal saline. The ZXC was perfused into the mouse stomachs twice daily, 40 times altogether. The mitomycin C was administrated by hypodermic injection once every two days, 10 times altogether. The efficacy estimation indices of the test included the life prolonging rate, stomach index, sialic acid (SA) content of serum of the nude mice with human stomach carcinoma. The test was repeated 3 times. Results: ①In the ZXC high, medium and low dose group, the life prolonging rate of the nude mice with human stomach carcinoma SGC 7901 were 57.78% to 72.03%(P <0.01), 42.22% to 56.59%(P <0.01), and ...